Perrigo Company plc (PRGO) Financials
PRGO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2025 | 9.8 billion | 5.4 billion |
| Dec. 31, 2024 | 9.6 billion | 5.3 billion |
| Sept. 30, 2024 | 11.2 billion | 6.6 billion |
| June 30, 2024 | 10.4 billion | 5.9 billion |
PRGO Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2025 | -90.0 million | 11.6 million |
| Dec. 31, 2024 | 274.9 million | 19.9 million |
| Sept. 30, 2024 | 15.1 million | 5.9 million |
| June 30, 2024 | -18.9 million | 23.0 million |
PRGO Net Income
No data available :(
PRGO Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2025 | - | - | - |
| Dec. 31, 2024 | 558.8 million | 3.6 billion | - |
| Sept. 30, 2024 | 1.5 billion | 4.3 billion | - |
| June 30, 2024 | 542.8 million | 3.6 billion | - |
PRGO Shares Outstanding
PRGO Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2025 | 25.5 million | 26.7 million | 281.2 million | - |
| Dec. 31, 2024 | 37.7 million | 27.9 million | 234.8 million | 140.1 million |
| Sept. 30, 2024 | 27.1 million | 26.0 million | 271.5 million | 154.6 million |
| June 30, 2024 | 28.4 million | 29.4 million | 300.8 million | 174.7 million |
PRGO Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2025 | 1.0 billion | 651.6 million |
| Dec. 31, 2024 | 1.1 billion | 752.4 million |
| Sept. 30, 2024 | 1.1 billion | 683.1 million |
| June 30, 2024 | 1.1 billion | 670.7 million |
PRGO Revenue by Segment
PRGO
List: Contenders
Price: $27.01
Dividend Yield: 4.39%
Forward Dividend Yield: 4.29%
Payout Ratio: -133.01%
Dividend Per Share: 1.16 USD
Earnings Per Share: -1.20 USD
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 680000
Ebitda: 274.7 millionMarket Capitalization: 3.7 billion
Average Dividend Frequency: 4
Years Paying Dividends: 23
DGR3: 26.56%
DGR5: 14.11%
DGR10: 14.21%
DGR20: 13.08%